0000950170-24-070605.txt : 20240607 0000950170-24-070605.hdr.sgml : 20240607 20240607160519 ACCESSION NUMBER: 0000950170-24-070605 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240605 FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kauffman Michael CENTRAL INDEX KEY: 0001364719 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 241029291 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 4 1 ownership.xml 4 X0508 4 2024-06-05 0001720580 Adicet Bio, Inc. ACET 0001364719 Kauffman Michael C/O ADICET BIO, INC. 131 DARTMOUTH STREET, FLOOR 3 BOSTON MA 02116 true false false false false Common Stock 2024-06-05 4 A false 5900 0.00 A 11800 D Common Stock 2024-06-05 4 S false 5900 1.43 D 5900 D Stock Option (Right to Buy) 1.44 2024-06-05 4 A false 26400 0.00 A 2034-06-04 Common Stock 26400 26400 D The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. /s/ Nick Harvey, Attorney-in-Fact 2024-06-07